Chemical Information | |
Antiviral agent ID | DrugRepV_1519 | |
Antiviral agent name | Cladribine | |
IUPAC Name | (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol | |
SMILES (canonical) | C1C(C(OC1N2C=NC3=C2N=C(N=C3N)Cl)CO)O | |
SMILES (isomeric) | C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(N=C3N)Cl)CO)O | |
Molecular Formula | C10H12ClN5O3 | |
Molecular Weight (g/mol) | 285.688 | |
InChl | InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1 | |
Common Name | Cladribine | |
Synonyms | (2R,3S,5R)-5-(6-amino-2-Chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol | 2-CdA | 2-Chloro-2'-deoxy-beta-adenosine | 2-Chloro-2'-deoxyadenosine | 2-chloro-6-amino-9-(2-Deoxy-beta-D-erythro-pentofuranosyl)purine | 2-chloro-Deoxyadenosine | 2-Chlorodeoxyadenosine | 2ClAdo | Cladribina | Cladribine | Cladribinum | CldAdo | |
Structural Information | |
|
|
Clinical Information | |
Category | Antineoplastic and Immunomodulating Agents
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Non Infectious Disease
| |
Primary Indication (Disease) | Lymphoproliferative diseases
| |
Secondary Indication | Zika virus (ZIKV) NA MEX_I_7 | |
Secondary Indication (Approaches) | Experimental-HTS | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.4 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Pre infection (1 hour)
| |
Secondary Indication (Duration of drug delivery) | 24-26 hours
| |
Secondary Indication (Drug concentration) | 13.8 μM
| |
Secondary Indication (Cell based assay) | Fluorescence-based assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 31.775 % ] | |
Reference | Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz.A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection..Cell Host Microbe. 2016 Aug 10;20(2):259-70. doi: 10.1016/j.chom.2016.07.004. Epub 2016 Jul 28. PMID:27476412
| |
Comment | Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.
| |